Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SYRE
SELLSpyre Therapeutics, Inc. · Healthcare · United States · $8.9B · Avg Vol: $164M/d
COMPANY DESCRIPTION
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD). The company utilizes advanced biologics engineering to create antibody candidates with superior efficacy and extended half-lives. Spyre's competitive position is built on its rational combination therapies and a pipeline designed to challenge established biologics in the immunology market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 2.3M | 0.9M | 0 | 0 | -62.0% | — | — | — | — |
| EPS | — | -0.75 | -5.71 | -3.18 | -1.98 | — | -2.12 | -2.95 | -3.13 | — |
| Shares | — | 86.8M | 86.8M | 60.3M | 78.2M | -10.0% | 86.8M | — | — | — |
| Debt | 5.1M | 4.6M | 0 | — | — | -8.5% | — | — | — | — |
| Equity | — | 50.3M | 184.0M | 517.8M | 715.2M | 142.3% | — | — | — | — |
| Op CF | — | -80.1M | -99.9M | -157.4M | -169.3M | — | -185.6M | — | — | — |
| Inv CF | — | 57.0M | -108.4M | -353.3M | -143.5M | — | — | — | — | — |
| Fin CF | — | 42.7M | 361.1M | 410.9M | 309.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SYRE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc.(you) | $8.9B | 32 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.0B | 30 | SELL |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 27 | SELL |
| IMVT | Immunovant, Inc. | $8.1B | 39 | HOLD |
| IBRX | ImmunityBio, Inc. | $7.4B | 26 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%